Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA's new draft guidance on naming biosimilars already drawing pushback
FDA's new draft guidance on naming biosimilars already drawing pushback
FDA's new draft guidance on naming biosimilars already drawing pushback
Submitted by
admin
on August 28, 2015 - 12:00pm
Source:
BioPharma Dive
News Tags:
FDA
drug names
biosimilars
Headline:
FDA's new draft guidance on naming biosimilars already drawing pushback
Do Not Allow Advertisers to Use My Personal information
